Johnson & Johnson Organizational Structure & Org Chart
Johnson & Johnson now reports two segments: Innovative Medicine and MedTech. The former Consumer Health business was separated in 2023, and the planned Orthopaedics separation had not yet been completed in the 2025 filing.
Johnson & Johnson organizational chart
Johnson & Johnson's reporting structure as of 2026-09. Drag to pan, scroll to zoom — or open it in QueryChart and edit it as your own.
- Industry
- Pharmaceuticals and medical technology
- Headquarters
- New Brunswick, New Jersey, United States
- Founded
- 1886
- Employees
- Approximately 138,200 (2025)
- CEO
- Joaquin Duato
- Revenue
- $94.2B worldwide sales (2025)
- Ownership
- Public
- Structure as of
- 2026-09
- Structure last reviewed
- 2026-09-24
About the company
Johnson & Johnson is a holding company whose operating companies research, develop, make and sell medicines and medical technologies. The 2025 annual report explicitly identifies two reportable segments. A chart that still includes Consumer Health or Kenvue as a current J&J operating segment is out of date.
The visual stops at a level supported by the company's filing and published leadership list. It includes major therapeutic and device fields to make the two segments useful to readers, but those product fields are not depicted as separate legal subsidiaries or as an unpublished internal reporting chain.
Innovative Medicine and MedTech
Innovative Medicine focuses on oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolic conditions. These are therapeutic areas within one reported segment. Tom Cavanaugh became worldwide chairman of Innovative Medicine in September 2026, succeeding Jennifer Taubert.
MedTech covers surgery, orthopaedics, cardiovascular and vision technologies. Tim Schmid is the published worldwide chairman. The company announced in October 2025 that it intended to separate Orthopaedics, but the 2025 annual report still includes the business within MedTech; this chart marks the intention in the text rather than prematurely treating it as an independent company.
Joaquin Duato is chairman and CEO, and the Executive Committee sets company strategy and priorities. Operating company managers carry out their own plans within that framework. The dotted branch map shows reported segments and fields, without asserting every operational reporting line.
Key leadership roles
Joaquin Duato
Chairman and Chief Executive Officer
Tom Cavanaugh
Executive Vice President, Worldwide Chairman, Innovative Medicine — Effective September 1, 2026.
Tim Schmid
Executive Vice President, Worldwide Chairman, MedTech
How this structure supports the business
The two-segment structure makes the post-Consumer Health company easier to understand and connects its two large health innovation portfolios to published leadership.
A clear date and note on Orthopaedics prevent a proposed transaction from being portrayed as completed. This matters because ownership and reporting can change materially when a separation closes.
Advantages and disadvantages
- Two published segments offer a clear top-level map.
- Each segment includes many operating companies and product fields not visible at this scale.
- Field labels help readers understand the medical portfolios.
- A therapeutic area is not necessarily a legal entity or a standalone manager chain.
Interesting facts
- J&J's 2025 annual report identifies two segments: Innovative Medicine and MedTech.
- Consumer Health was separated in 2023.
- The company said it intended to separate Orthopaedics, but the 2025 filing still includes it in MedTech.
- Tom Cavanaugh succeeded Jennifer Taubert as Innovative Medicine worldwide chairman in September 2026.
- J&J reported approximately 138,200 employees in its 2025 report.
Related organization charts
Frequently asked questions
What are Johnson & Johnson's current business segments?
Innovative Medicine and MedTech.
Is Consumer Health still a J&J segment?
No. It was separated in 2023 and does not appear as a current reporting segment.
Has Orthopaedics already left J&J?
The 2025 report describes a planned separation; this chart keeps Orthopaedics within MedTech until a completed transaction is verified.
Use this org chart template
Open the dated Johnson & Johnson business map in QueryChart and adapt the editable groups to your own organization.
